Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 2, 2014

Study Completion Date

April 2, 2014

Conditions
TetanusAcellular PertussisDiphtheria
Interventions
BIOLOGICAL

Boostrix

Single dose intramuscular administration.

Trial Locations (20)

11733

GSK Investigational Site, East Setauket

15241

GSK Investigational Site, Upper Saint Clair

16505

GSK Investigational Site, Erie

32209

GSK Investigational Site, Jacksonville

40004

GSK Investigational Site, Bardstown

44109

GSK Investigational Site, Cleveland

44121

GSK Investigational Site, Cleveland

60614

GSK Investigational Site, Chicago

68131

GSK Investigational Site, Omaha

72401

GSK Investigational Site, Jonesboro

77030

GSK Investigational Site, Houston

80401

GSK Investigational Site, Golden

84095

GSK Investigational Site, South Jordan

84109

GSK Investigational Site, Salt Lake City

85213

GSK Investigational Site, Mesa

85283

GSK Investigational Site, Tempe

90274

GSK Investigational Site, Rolling Hills Estates

92835

GSK Investigational Site, Fullerton

06360

GSK Investigational Site, Norwich

01801

GSK Investigational Site, Woburn

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01738477 - Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults | Biotech Hunter | Biotech Hunter